John Gordon McVie
|Alma mater|| University of Edinburgh, |
|Known for||Cancer research, Clinical Trials, Personalised Care|
|Fields||Cancer research, Clinical Trials|
|Institutions|| Netherlands Cancer Institute |
European Institute of Oncology
Italian Institute for Molecular Oncology
Cancer Research Campaign
Cancer Research UK
|Doctoral advisor||Gordon Hamilton-Fairley|
Professor John Gordon McVie BSc (Hons), MBChB, M.D., FRCP, FRCPE, FRCPSGlas, FMedSci, DSc (born 13 January 1945) is an international authority on the treatment and research of cancer. He has written over 350 peer reviewed articles, editorials and books.
He has served on several committees including the American Association for Cancer Research and the American Society of Clinical Oncology, and the boards of the National Cancer Institutes of France, Italy and the Netherlands. In the UK, he has served on the boards of cancer institutes including the Beatson Institute for Cancer Research, the Institute for Cancer Research, and the Christie Hospital.
He is currently visiting professor, King's College London, Senior Clinical Research Consultant at the Italian Institute for Molecular Oncology (IFOM) Milan, and Non Executive Director at Ellipses Pharma ltd, UK Chair of ORIL, Australia and Chair of the European Alliance for Personalised Medicine.
He has contributed several substantial additions to the field of cancer care including establishing localised, more pin-point, administration of chemotherapy, and encouraging the use of chemotherapy for the treatment of lung cancer throughout the EU. He has also emphasised the importance of adjusting a patient's management according to their ethnicity.
McVie obtained his degrees in science and medicine at the University of Edinburgh in 1971 and became a lecturer in Therapeutics and Materia Medica, University of Edinburgh.
In 1975 McVie became the Foundation Senior Lecturer at the Cancer Research Campaign Oncology Unit (currently Beatson West of Scotland Cancer Centre) at the University of Glasgow. Under Gordon Hamilton-Fairley and Sir Kenneth Calman, he trained in the United States, spending sabbaticals at the NCI, Bethseda, Paris, Sydney, Australia and Amsterdam.
In 1979, McVie became the Clinical Research Director at the National Cancer Institute of the Netherlands, and Consultant in Medical Oncology at the Antoni van Leewenhoek hospital in Amsterdam. He developed a drug development laboratory, and a clinical research unit, for Phase 1 and 2 drugs, plus establishing intraperitoneal therapy in ovarian cancer and limb perfusion in localised sarcoma and melanoma.
At the European Organisation for Research and Treatment of Cancer (EORTC) he started the Lung cancer group and researched standard chemotherapy / irradiation regimes which were adopted for small and non small cell lung cancer, mesothelioma and thymoma. As Chair of the Pharmacology and Metabolism Group he developed a platform for young investigators to present new molecules and their pharmacology. He was elected President of EORTC and initiated the present Drug Development Group in Brussels, and with NCI support, the European New Drug Development Network and the joint EORTC, NCI, CRC Formulation Committee for anti cancer molecules.
In 1989 McVie became the Scientific Director then Director General of the Cancer Research Campaign. During this time over 60 new drugs were taken from laboratory to clinical trial, and carboplatin, temozolomide, olaparib and abiraterone, all important “breakthrough” anticancer drugs, emerged. In the UK he was one of the architects of the Cancer Trials Networks in Scotland, Wales, and England, and was a founding member of the National Cancer Research Institute, UK.
Having overseen a doubling of Cancer Research Campaign charitable income, he led the merger with ICRF to found Cancer Research UK (CRUK), the largest cancer charity in Europe.
In 2002 McVie became joint CEO of Cancer Research UK with Sir Paul Nurse, where he continued to support new molecule testing and support start-up companies.
Then in 2003 McVie founded a new endeavour, Cancer Intelligence, then with the late Umberto Veronesi - a free online global cancer journal ecancer.org, which was published for eleven years in Zurich, then moved to become a UK charity.
In 2004 McVie became a Senior Consultant of Clinical Research at the European Institute of Oncology, Milan. He set up a clinical research unit to test new molecules and devices, and synergised the new institute with other leading cancer centres throughout the world.
In 2016 he joined the Italian Institute for Molecular Oncology in Milan.
1967 Gunning Victoria Jubilee Prize in Pathology
1977 Honeyman Gillespie Lecturer in Medicine
1978 Visiting Fellow, University of Paris, Department of Medical Oncology
1979 Visiting Fellow, Netherlands Cancer Institute, Amsterdam
1980 Consultant, Carcinogenesis of Cytostatic Drugs, International Agency Research in Cancer, WHO, Lyon
1983 Visiting Professor, University of Sydney, NSW Australia
1990-1996 Visiting Professor, British Postgraduate Medical Federation, London University
1990-1998 Chairman UICC Fellowships Program and Board member (Union Internationale Contre le Cancer/International Union Against Cancer)
1994-1997 President, European Organisation for Research and Treatment of Cancer
1994-2002 First European Editor of Journal of the National Cancer Institute, US
1995 King of Jordan’s Medal for Excellence in Science
1996 DSc (Hon) University of Abertay, Dundee
1996-2000 Visiting Professor, University of Glasgow
1997 DSc (Hon) University of Nottingham
1998 FMedSci (Fellow of the Academy of Medical Sciences)
1999 DSc (Hon) University of Portsmouth
2000 Semmelweis Medal for Excellence in Science, Budapest
2000 Medal of the National Scientific Research Fund of Belgium
2001 Silver Medal, Royal Scottish Society of Arts
2001 Medal of the National Cancer Society of Greece
2001 FRCSE (Hon) (Fellow of the Royal College of Surgeons, Ed
2002 DSc (Hon) Napier University, Edinburgh
2003-2006 Visiting Professor in Cancer Medicine, University of Cardiff
2005 DSc(Hon) University of Ghent, Belgium
2004 Fellow of the European Academy of Cancer Sciences
2005 MD (Hon), University of Bath
2017 Fellow of the Association of Cancer Physicians, UK
The Institute of Cancer Research is a public research institute and a constituent college of the University of London in London, United Kingdom, specialising in oncology. It was founded in 1909 as a research department of the Royal Marsden Hospital and joined the University of London in 2003. It has been responsible for a number of breakthrough discoveries, including that the basic cause of cancer is damage to DNA.
Vincent Theodore DeVita Jr. is the Amy and Joseph Perella Professor of Medicine at Yale Cancer Center, and a Professor of Epidemiology and Public Health. He directed the Yale Cancer Center from 1993 to 2003. He has been president of the American Cancer Society (2012-2013). He is internationally recognized as a pioneer in the field of oncology for his work on combination-chemotherapy treatments.
The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.
M. Krishnan Nair is a leading oncologist working in India. He is the founding director of the Regional Cancer Centre, Thiruvananthapuram, a director of the S.U.T. Institute of Oncology, and Trivandrum Cancer Center(TCC), part of SUT ROYAL HOSPITAL in Thiruvananthapuram(Trivandrum) and a professor at the Amrita Institute of Medical Sciences & Research in Kochi. He received the Padma Shri award from the President of India.
The European Organisation for Research and Treatment of Cancer (EORTC) is a unique pan-European non-profit clinical cancer research organisation established in 1962 operating as an international association under Belgium law. It develops, conducts, coordinates and stimulates high-quality translational and clinical trial research to improve the survival and quality of life of cancer patients. This is achieved through the development of new drugs and other innovative approaches, and the testing of more effective therapeutic strategies, using currently approved drugs, surgery and/or radiotherapy in clinical trials conducted under the auspices of a vast network of clinical cancer researchers supported by 220 staff members based in Brussels. EORTC has the expertise to conduct large and complex trials especially specific populations such as the older patient and rare tumours.
The European Institute of Oncology is a non-profit private-law comprehensive cancer centre located in Milan, Italy. It is a clinic, a research centre and a training institution.
The Beatson West of Scotland Cancer Centre is a specialised cancer care centre in Glasgow, Scotland. Until recently it had facilities in Gartnavel General Hospital, the Western Infirmary and Glasgow Royal Infirmary. As part of the NHS Greater Glasgow and Clyde Acute Services Review, the centre is being centralised within new facilities at the Gartnavel General Hospital site.
Frank S. Walsh PhD, DSc (Hon.) FMedSci, FKC, corrFRSE is a British-born neuroscientist. He is best known for his work on the understanding of the role of cell adhesion molecules in the development and regeneration of the nervous system. He is the author of over 250 publications in peer-reviewed journals.
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is a National Cancer Institute (NCI)-designated comprehensive cancer center located in Baltimore, Maryland.
Professor Dame Janet Elizabeth Siarey Husband is Emeritus Professor of Radiology at the Institute of Cancer Research. She had a career in diagnostic radiology that spanned nearly 40 years, using scanning technology to diagnose, stage, and follow-up cancer. She continues to support medicine and research as a board member and advisor for various organisations.
Edison T. Liu, M.D., is the president and CEO of The Jackson Laboratory, and was the president of Human Genome Organization, HUGO from 2007-2013.
Professor David James Kerr CBE, MA MD DSc FRCP FRCGP (Hon) FMedSci is a British cancer researcher. His primary area of research is treatment and management of colorectal cancer.
John E. Niederhuber, MD was the 13th director of the National Cancer Institute (NCI), from 2006 until July, 2010, succeeding Andrew von Eschenbach, who went on to become a director at biotechnology firm BioTime. A nationally renowned surgeon and researcher, Dr. Niederhuber has dedicated his four-decade career to the treatment and study of cancer - as a professor, cancer center director, National Cancer Advisory Board chair, external advisor to the NCI, grant reviewer, and laboratory investigator supported by NCI and the National Institutes of Health. He is now Executive Vice President/CEO Inova Translational Medicine Institute and Inova Health System and Co-Director, Johns Hopkins Clinical Research Network.
Professor Sir Michael Adrian Richards, CBE, MD, DSc (Hon), FRCP is a British oncologist. From 1999 to 2013 he was the National Cancer Director in the UK Government's Department of Health. He was appointed to be the Chief Inspector of Hospitals in the Care Quality Commission on 31 May 2013. and was said by the Health Service Journal to be the third most powerful person in the English NHS in December 2013.
Paul Workman, is a British scientist noted for his work on the discovery and development of pharmaceutical agents in the field of oncology.
Cora Sternberg is an American medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital, serving as a member of the Genitourinary (GU) Oncology Program. Dr. Sternberg facilitates the continued growth and development of clinical and translational research programs in GU malignancies, with a particular emphasis on expanding the overall research portfolio. As Clinical Director of the Englander Institute for Precision Medicine (EIPM), Dr. Sternberg will develop strategies to incorporate genomic sequencing and precision medicine throughout the Weill Cornell Medicine and NewYork-Presbyterian healthcare network, including Lower Manhattan, Brooklyn and Queens.
Michelle Haber is an Australian cancer researcher.
Silvio Garattini is an Italian scientist, pharmacology research scientist, physician and professor in chemotherapy and pharmacology and director of the Mario Negri Institute for Pharmacological Research.
(Robert) Charles Swanton is British physician scientist specialising in oncology and cancer research. Swanton is a senior group leader at London's Francis Crick Institute, Royal Society Napier Professor in Cancer and thoracic medical oncologist at University College London and University College London Hospitals, co-director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK.
Barry Victor Lloyd Potter MAE FMedSci is Professor of Medicinal & Biological Chemistry at the University of Oxford, Wellcome Trust Senior Investigator and a Fellow of University College, Oxford.